These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28148339)

  • 21. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis.
    Maidment ID; Fox CG; Boustani M; Rodriguez J; Brown RC; Katona CL
    Ann Pharmacother; 2008 Jan; 42(1):32-8. PubMed ID: 18056833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapies for Alzheimer's disease.
    Melnikova I
    Nat Rev Drug Discov; 2007 May; 6(5):341-2. PubMed ID: 17539055
    [No Abstract]   [Full Text] [Related]  

  • 23. Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis.
    Kishi T; Matsunaga S; Oya K; Nomura I; Ikuta T; Iwata N
    J Alzheimers Dis; 2017; 60(2):401-425. PubMed ID: 28922160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Memantine brakes Alzheimer's dementia. The NMDA antagonist is effective in severe cases, too].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():21. PubMed ID: 14579479
    [No Abstract]   [Full Text] [Related]  

  • 25. Discontinuing donepezil or starting memantine for Alzheimer's disease.
    Suzuki T
    N Engl J Med; 2012 Jun; 366(23):2227-8; author reply 2228. PubMed ID: 22670911
    [No Abstract]   [Full Text] [Related]  

  • 26. Discontinuing donepezil or starting memantine for Alzheimer's disease.
    Schneider LS
    N Engl J Med; 2012 Mar; 366(10):957-9. PubMed ID: 22397659
    [No Abstract]   [Full Text] [Related]  

  • 27. Alzheimer's disease.
    Cummings JL
    N Engl J Med; 2004 Jul; 351(1):56-67. PubMed ID: 15229308
    [No Abstract]   [Full Text] [Related]  

  • 28. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics.
    Caltagirone C; Bianchetti A; Di Luca M; Mecocci P; Padovani A; Pirfo E; Scapicchio P; Senin U; Trabucchi M; Musicco M;
    Drugs Aging; 2005; 22 Suppl 1():1-26. PubMed ID: 16506439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficacy of memantine in the treatment of Alzheimer's disease].
    Molinuevo Guix JL; Lladó Plarrumaní A
    Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors.
    Jones RW
    Int J Geriatr Psychiatry; 2010 Jun; 25(6):547-53. PubMed ID: 20049770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial.
    Scherer RW; Drye L; Mintzer J; Lanctôt K; Rosenberg P; Herrmann N; Padala P; Brawman-Mintzer O; Burke W; Craft S; Lerner AJ; Levey A; Porsteinsson A; van Dyck CH;
    Trials; 2018 Jan; 19(1):46. PubMed ID: 29347996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients.
    Zhang N; Wei C; Du H; Shi FD; Cheng Y
    Dement Geriatr Cogn Disord; 2015; 40(1-2):85-93. PubMed ID: 26066622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacological interventions for apathy in Alzheimer's disease].
    Heupel-Reuter M; Klöppel S; Bauer JM; Voigt-Radloff S
    Z Gerontol Geriatr; 2019 Aug; 52(5):457-459. PubMed ID: 31297590
    [No Abstract]   [Full Text] [Related]  

  • 35. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis.
    Matsunaga S; Kishi T; Iwata N
    Int J Neuropsychopharmacol; 2014 Dec; 18(5):. PubMed ID: 25548104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New options for the pharmacotherapy of Alzheimer disease after the approval of memantine? Re the article from DMW 8/2005].
    Wellhöfer B
    Dtsch Med Wochenschr; 2006 Feb; 131(6):284. PubMed ID: 16463237
    [No Abstract]   [Full Text] [Related]  

  • 37. Cessation of donepezil is associated with clinical decline in patients with moderate-to-severe Alzheimer's disease compared to continuation of donepezil or addition or substitution of memantine.
    Tariot PN
    Evid Based Med; 2013 Apr; 18(2):62-3. PubMed ID: 22736656
    [No Abstract]   [Full Text] [Related]  

  • 38. Recent Progress in the Pharmacotherapy of Alzheimer's Disease.
    Khoury R; Patel K; Gold J; Hinds S; Grossberg GT
    Drugs Aging; 2017 Nov; 34(11):811-820. PubMed ID: 29116600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Advances in Alzheimer's disease treatment].
    Nourhashémi F
    Rev Med Interne; 2006 Aug; 27(8):585-7. PubMed ID: 16782240
    [No Abstract]   [Full Text] [Related]  

  • 40. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
    Rodda J; Morgan S; Walker Z
    Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.